Member Info for Uncanny

Yes indeed, BUT don’t forget the retail placing was twice over subscribed just 4 months ago, so plenty of support IMHO.

Enjoy your jolly’s!

Sorry posted half way through!

Hi Nick

I agree in part.

IMHO, TheoremRx has been the catalyst of the heady days demise of a double digit share price to where we are today and l for one am very angry at the way THX have acted, wasting (stripping out 12 months for Covid 19 lockdown) the good part of 2 years of time, albeit VAL have continued to focus on rebuilding and rebranding the ship despite this. Glad to see the back of them TBH (but disappointed) and right for ME to finally pull the plug BUT there was nothing else on the table so nothing to lose by extending 3 months, but happy to see he had some contingency plan in place….. Also, l guess by cancelling the 201 LOI really messes up THX’s plans now - Karma!

I understand that 201 is still a valuable asset and ME is right to reform and extend the life as despite the debacle of THX, they saw commercial value in the IP and did indeed still want 201 which has been through clinical trials….so if of value to THX, it must be of value to others so let’s see how the new interest goes with the consortium whether in Taiwan or not, or indeed anyone else and interesting to see the new SPV will be a concentrated prostate cancer vehicle for encompassing not only 201 but CLX et al.

Similarly, Ambrose extension ends May l believe and they are serious (unlike THX ) commercial partners last completing on their cystic fibrosis IP at the end of 2024 so they are serious unlike THX:

https://www.ambrosehc.com/news/option-exercised-for-global-rights-to-renzapride-for-use-in-rare-disease-indication

Then we get to CLX and what a great IP it is and my main reason to buy a 5.8% stake as this IMHO, NAI, DYOR will be a behemoth - ME has been out on the road recently in the UK and abroad promoting at a multitude of bio events as witnessed on Linkedln for an early deal l guess, so very much look forward to seeing development in lab and further news and updates.

Costs have been significantly cut and l know you have your gripe with MT, lol. £200k pa saving on redundancies, plus at board level bringing in products in-house in to the lab saves a fortune and even back to SD days what a shred move to close the £14k pm London office to the midlands at £4k pm head office including a working lab and two staff!

£1.2mn is a crazy valuation IMHO and with the assets and potential in the IP l really think at least £10mn would be fair so VAL at present is valued to fail as you say and hopefully a double and much more to come with BoD with skin in the game so not just taking a salary for a feee ride but hurt when we hurt!

Hi Nick

I agree in part.

IMHO, TheoremRx has been the catalyst of the heady days demise of a double digit share price to where we are today and l for one am very angry at the way THX have acted, wasting (stripping out 12 months for Covid 19 lockdown) the good part of 2 years of time, albeit VAL have continued to focus on rebuilding and rebranding the ship despite this. Glad to see the back of them TBH (but disappointed) and right for ME to finally pull the plug BUT there was nothing else on the table so nothing to lose by extending 3 months, but happy to see he had some contingency plan in place….. Also, l guess by cancelling the 201 LOI really messes up THX’s plans now - Karma!

I understand that 201 is still a valuable asset and ME is right to reform and extend the life as despite the debacle of THX, they saw commercial value in the IP and did indeed still want 201 which has been through clinical trials….so if of value to THX, it must be of value to others so let’s see how the new interest goes with the consortium whether in Taiwan or not, or indeed anyone else and interesting to see the new SPV will be a concentrated prostate cancer vehicle for encompassing not only 201 but CLX et al.

Similarly, Ambrose extension ends May l believe and they are serious (unlike THX ) commercial partners last completing on their cystic fibrosis IP at the end of 2024 so they are serious unlike THX:

https://www.ambrosehc.com/news/option-exercised-for-global-rights-to-renzapride-for-use-in-rare-disease-indication

Then we get to CLX and what a great IP it is and my main reason to buy a 5.8% stake as this IMHO, NAI, DYOR will be a behemoth - ME has been out on the road recently in the UK and abroad promoting at a multitude of bio events as witnessed on Linkedln for an early deal l guess, so very much look forward to seeing development in lab and further news and updates.

Costs have

Well a nice bout of buying again today and yesterday, so look forward to what next week brings.

Have a good weekend all.

Thanks Porky and back to sleep again now please.

Thanks Porky and back to sleep again now please.

Thanks for sharing Best and sounds like the new 201 / PC SPV will be in better shape, more robust and longer patent light life, plus the extra PC bolt ons in CLX etc. ME mentions in the video.

You would hope therefore that the new SPV could attract a much higher value than THX offered with the consortium / Taiwan people mentioned in the RNS?!

GLA and be nice to see the SP bounce back to at least the placing price for starters, as massively overdone IMHO, NAI.

LOL, yes I chat with Nick a fair bit and rose tinted or a measured outlook?

Yes quite aware of that fact thanks, LOL

Porky, I thought you had gone my old fruit and reincarnated as Viera, LOL

Hoping to see some buyers back today as many were waiting in the wings for THX to conclude one way or another and now full steam ahead again.

GLA

Well that’s the $64,000 question isn’t it…… one can assume it’s connected to the consortium VAL are in early discussions with re: 201 that ME eludes to in today’s RNS.

I am sure all will be revealed and quite savvy that ME had a plan B up his sleeve as a contingency in realisation of THX’s past record of disappointing!

The silver lining with THX is that VAL might come out of this smelling of roses with a more robust dataset and a more valuable 20 year patent life, opening the door also of potentially offering 301 which is based on 201 tech.

Indeed Jinky and l know some wanting to buy in a half decent size were faced with the situation of not been able to get any stock.

Think this could bounce back quite nicely IMHO, NAI

GLA

I would like to say that this news has been actually taken quite positively looking at the buys going through and general feeling here.

Onwards and upwards I hope!

You mean cutting costs, getting rid of loose baggage - both head count and IP plus now THX, albeit it was well overdue so good riddens!

We now have to look forward to Ambrose and CLX updates, the new SPV, new evaluations and now wait with bated breath on the new consortium in discussion for the polished 201 SPV we were told about this morning!

Victor Meldrew has arrived, LOL

A bit telling that only £20K worth of stock has been traded this morning which the largest trades are buys.

Valuation of £1.5mn is bonkers with or without 201!

What was interesting was the wording of the RNS:

"The termination of the LOI follows notification by TheoremRx of a decision not to proceed with an amendment to the LOI to return the territory of Taiwan"

> Taiwan?

"VAL201 will be moved to a prostate cancer focussed special purpose vehicle within ValiRx and plans to file IP to extend the patent life. The Company has received interest from a new consortium"

> Taiwan?

"regarding the asset and is in early stage discussions with charities regarding possible support for clinical development."

> ME to get funding without using shareholder funds I guess, as he is good at getting grant funding

"Whilst the decision to terminate the LOI is obviously disappointing, we have contingencies for this eventuality. "

> Anticipated and planned for which is good

Moving VAL201 into a prostate cancer focussed SPV will give us the opportunity to file and develop new, ValiRx owned, IP based on in house technical knowhow to reset the patent coverage back to 20 years with proof of concept data for Val201 2.0 and to seek new partnerships from a position of strength

> this was one of the weaknesses of 201 mentioned by posters previously so a new patent life and more robust offering should add more value and interest.

So not all bad!

Well we were priced in for failure so nothing new on that front.

Obviously VAL planned for this contingency and is why they have an another interested consortium, plus the Taiwan amendment was contested by THX so l guess one and the same?

Some will be relieved and happy at this news l guess that the TRX shackles are finally removed.

Well the silver lining is that Viera and many other got what they wanted, the IP is going to be placed in a SPV and there is a new interested party - l wonder what the interest in Taiwan is?

Waiting for news that all.